Published in Curr Pharm Des on January 01, 2006
Role of CD28 in fatal autoimmune disorder in scurfy mice. Blood (2007) 1.04
IDO and regulatory T cell support are critical for cytotoxic T lymphocyte-associated Ag-4 Ig-mediated long-term solid organ allograft survival. J Immunol (2011) 1.00
TCR/CD3 mediated stop-signal is decoupled in T-cells from Ctla4 deficient mice. Immunol Lett (2007) 0.99
CTLA4-Ig interacts with cultured synovial macrophages from rheumatoid arthritis patients and downregulates cytokine production. Arthritis Res Ther (2009) 0.92
Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an "innocent bystander". Toxins (Basel) (2014) 0.92
Cytotoxic T lymphocyte antigen 4 immunoglobulin modified dendritic cells attenuate allergic airway inflammation and hyperresponsiveness by regulating the development of T helper type 1 (Th1)/Th2 and Th2/regulatory T cell subsets in a murine model of asthma. Clin Exp Immunol (2011) 0.85
Anti-cytotoxic T lymphocyte antigen-4 antibodies in melanoma. Clin Cosmet Investig Dermatol (2013) 0.85
Functional interaction of CD154 protein with α5β1 integrin is totally independent from its binding to αIIbβ3 integrin and CD40 molecules. J Biol Chem (2012) 0.83
Endogenous memory CD8 T cells directly mediate cardiac allograft rejection. Am J Transplant (2014) 0.83
CTLA4-Ig immunosuppressive activity at the level of dendritic cell/T cell crosstalk. Int Immunopharmacol (2013) 0.82
Immunotherapy of Ovarian Cancer: The Role of Checkpoint Inhibitors. J Immunol Res (2015) 0.82
Lessons and limits of mouse models. Cold Spring Harb Perspect Med (2013) 0.78
B cells as a target of immune modulation. Ann Indian Acad Neurol (2009) 0.76
Evaluation of Anti-inflammatory Effects of Steroids and Arthritis-Related Biotherapies in an In Vitro Coculture Model with Immune Cells and Synoviocytes. Front Immunol (2016) 0.75
Gene expression of mesothelioma in vinylidene chloride-exposed F344/N rats reveal immune dysfunction, tissue damage, and inflammation pathways. Toxicol Pathol (2014) 0.75
Placental immune editing switch (PIES): learning about immunomodulatory pathways from a unique case report. Oncotarget (2016) 0.75
Cytotoxic T lymphocyte antigen 4-immunoglobulin G is a potent adjuvant for experimental allergen immunotherapy. Clin Exp Immunol (2013) 0.75
IL-22 defines a novel immune pathway of antifungal resistance. Mucosal Immunol (2010) 1.76
IL-6 inhibits the tolerogenic function of CD8 alpha+ dendritic cells expressing indoleamine 2,3-dioxygenase. J Immunol (2001) 1.46
CD40 ligation ablates the tolerogenic potential of lymphoid dendritic cells. J Immunol (2001) 1.25
Balancing inflammation and tolerance in vivo through dendritic cells by the commensal Candida albicans. Mucosal Immunol (2009) 1.20
Cutting edge: spontaneous rejection of poorly immunogenic P1.HTR tumors by Stat6-deficient mice. J Immunol (2000) 1.13
IFN-gamma inhibits presentation of a tumor/self peptide by CD8 alpha- dendritic cells via potentiation of the CD8 alpha+ subset. J Immunol (2000) 1.10
Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: superiority of B7-1 over B7-2 for active tumor immunization. J Immunol (1996) 1.09
Immunization of HLA-A2+ melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12. Clin Cancer Res (2001) 1.09
Positive regulatory role of IL-12 in macrophages and modulation by IFN-gamma. J Immunol (2001) 1.07
Antigen recognition and allogeneic tumor rejection in CD8+ TCR transgenic/RAG(-/-) mice. J Immunol (1997) 1.04
Intranasally delivered siRNA targeting PI3K/Akt/mTOR inflammatory pathways protects from aspergillosis. Mucosal Immunol (2009) 1.03
Epitope spreading upon P815 tumor rejection triggered by vaccination with the single class I MHC-restricted peptide P1A. Int Immunol (2001) 1.00
Blockade of T cell activation using a surface-linked single-chain antibody to CTLA-4 (CD152). J Immunol (2000) 0.96
Absence of CTLA-4 lowers the activation threshold of primed CD8+ TCR-transgenic T cells: lack of correlation with Src homology domain 2-containing protein tyrosine phosphatase. J Immunol (2001) 0.94
CD8+ cell activation to a major mastocytoma rejection antigen, P815AB: requirement for tum- or helper peptides in priming for skin test reactivity to a P815AB-related peptide. Eur J Immunol (1995) 0.86
Transplantation and the CD28/CTLA4/B7 pathway. Transplant Proc (2001) 0.83
Rational development of tumour antigen-specific immunization in melanoma. Ther Immunol (1995) 0.81
Targeting metabotropic glutamate receptors in neuroimmune communication. Neuropharmacology (2012) 0.79
Enhancement by IL-12 of the cytolytic T lymphocyte (CTL) response of mice immunized with tumor-specific peptides in an adjuvant containing QS21 and MPL. Eur Cytokine Netw (1999) 0.78
IL-12 is both required and sufficient for initiating T cell reactivity to a class I-restricted tumor peptide (P815AB) following transfer of P815AB-pulsed dendritic cells. J Immunol (1996) 0.78
Multiple point mutations in an endogenous retroviral gene confer high immunogenicity on a drug-treated murine tumor. J Immunol (1995) 0.77
Cytotoxic T lymphocyte antigen 4-immunoglobulin G is a potent adjuvant for experimental allergen immunotherapy. Clin Exp Immunol (2013) 0.75